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Brief Technique ReportsAortic valve replacement and mitral valve repair as treatment of
complications after percutaneous core valve implantation
Chiara Comoglio, MD,a Massimo Boffini, MD,a Suad El Qarra, MD,a Fabrizio Sansone, MD,a
Maurizio D’Amico, MD,b Sebastiano Marra, MD,b and Mauro Rinaldi, Professor,a Turin, ItalyStandard aortic valve replacement is the gold standard for
the treatment of severe aortic stenosis but transcatheter pro-
cedure can be performed in selected patients with important
comorbidities or absolute contraindication for standard sur-
gical approach. Careful multidisciplinary evaluation of each
single case is fundamental in order to tailor the appropriate
approach for every patient.
CLINICAL SUMMARY
We describe the case of a 66-year-old man who had sur-
gical intervention for a core valve malfunction 3 months
after transfemoral implantation. The patient was scheduled
for percutaneous aortic valve implantation (PAVI) because
of the presence of numerous risk factors, such as obesity
(body mass index, 35%) and myelodysplasia. The main
concern about elective standard aortic valve replacement
was related to the patient’s pulmonary function. As a result
of a history of smoking and obesity, he had severe chronic
pulmonary disease (forced expiratory volume in 1 second,
<35%) and obstructive sleep apnea syndrome requiring
noninvasive mechanical ventilation.
The patient presented with rapid worsening of dyspnea.
An echocardiogram showed a severely calcified aortic steno-
sis with left ventricular hypertrophy and good ejection frac-
tion (60%). For this reason, he was evaluated for aortic
valve replacement. Preoperative coronary angiographic
analysis revealed normal coronary arteries. Despite a relative
low EuroSCORE, PAVI was indicated because of multiple
comorbidities and requested by the patient.
PAVI with a core valve bioprosthesis was performed with-
out procedural complications. Only a second balloon dilata-
tion was required for a moderate paraprosthetic aortic
regurgitation detected immediately after the procedure, and
a mild-to-moderate paraprosthetic aortic regurgitation re-
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plicated by several episodes of sustained ventricular
tachycardia and 1 episode of ventricular fibrillation requiring
automatic cardiac defibrillator implantation. However, no
electrocardiographic abnormalities or cardiac enzyme release
were detected. The postprocedural rehabilitation period was
characterized by slow functional recovery with many epi-
sodes of ventricular tachycardia. One month later, the patient
was readmitted to the intensive care unit for progressive bi-
ventricular failure and ventricular arrhythmia. Echocardio-
graphic analysis confirmed moderate paraprosthetic aortic
regurgitation with preserved left ventricular ejection fraction
but with progressive left ventricular dilatation. Cardiac
rhythmwas restored with lidocaine and amiodarone infusion,
but acute respiratory failure occurred, requiring intubation
and mechanical ventilation for about 1 week.
Two months later, the patient reported progressive
worsening of general conditions, with fever, shivering, and
leukocytosis. A single blood culture was positive for coryne-
bacterium. An echocardiogram showed what appeared to be
a pseudoaneurysm of the posterior aortic annulus. Aortic re-
gurgitation was stable, but severe mitral regurgitation was
detected as a result of anterior leaflet perforation, enhancing
the suspicion of acute endocarditis. For this reason, 3 months
after the percutaneous procedure, the patient underwent
surgical intervention.
After median sternotomy, cardiopulmonary bypass was
instituted as usual. After clamping the aorta, cardioplegia
was administered in the aortic root without success be-
cause of severe aortic regurgitation, and selective cardio-
plegia directly into the coronary ostia was required. Once
the aorta was opened, despite a well-positioned aortic
valve prosthesis, we found a bioprosthetic metal support
protruding for about 4 cm in the ascending aorta, causing
severe obstruction of the left main trunk ostium (Figure 1),
and only small vegetation on the cusps was found, with-
out annular involvement (Figure 1). The proximal part of
the support was about 5 cm into the left ventricular out-
flow tract, leaning against the anterior mitral leaflet and
causing leaflet perforation (Figure 2). A paraprosthetic
leak was found at the level of the left and noncoronary
cusps, where an important calcification was present. To
remove the prosthesis, the aortic root was filled with ice
water to crimp the core valve, and after a gentle squeeze
of the aorta, the core valve was accurately detached fromrdiovascular Surgery c Volume 138, Number 4 1025
Brief Technique ReportsFIGURE 1. A, Prosthetic endocarditis. B, Intraoperative evidence of severe left coronary ostial obstruction caused by core valve metal support and para-
prosthetic leak.the aortic wall itself and successfully removed (Figure 2,
B). A 23-mm Carpentier–Edwards aortic valve prosthesis
was implanted. Anterior mitral leaflet injury was repaired
with a pericardial patch.
The postoperative course was uneventful. The patient was
discharged on the seventh postoperative day. Predischarge
echocardiographic analysis showed correct function of the
aortic bioprosthesis and no residual mitral regurgitation.1026 The Journal of Thoracic and Cardiovascular SuDISCUSSION
Some considerations of our experience are mandatory.
First, the design of the core valve is quite bulky, with
a part of the prosthesis leaning into the left ventricle with
possible interference with the mitral valve apparatus. More-
over, the core valve metal support protrudes into the as-
cending aorta with the risk of left main obstruction, as in
our case.FIGURE 2. A, Anterior mitral leaflet perforation. B, Core valve appearance. LVOT, Left ventricular outflow tract.rgery c October 2009
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valve replacement was uneventful, despite the important co-
morbidities of the patient that suggested PAVI. Therefore anTotally percutaneous valve replacem
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Recently, the feasibility and safety of percutaneous aortic
valve replacement (PAVR) has been reported in the treat-
ment of degenerative aortic valve stenosis in patients at
high-risk for surgical aortic valve replacement (AVR).1
However, so far this therapy has been limited to patients
with severe stenosis of the native valve. We report the
case of a patient with severe aortic regurgitation owing to
bioprosthesis dysfunction who was successfully treated by
implantation of a CoreValve (CoreValve Inc, Irvine. Calif)
prosthesis with a totally percutaneous approach.
CLINICAL SUMMARY
An 84-year-old woman, with previous surgical AVR with
a bioprosthesis (Biocor 25 mm stentless; (Biocor Industria e
Pesguisa Ltda, BeloHorizonte, Brazil) and cardiac pacemaker
implantation for severe aortic stenosis in 1998, was admitted
to a community hospital because of pulmonary edema. Co-
morbidity included hypertension, chronic renal failure, and
previous left hemicolectomy for bowelmalignancy. Transtho-
racic echocardiogram revealed a severe transprosthetic aortic
regurgitation caused by leaflet degeneration and prolapse;
the left ventricle was enlarged with moderate impairment of
systolic function. Despite medical treatment, clinical status
rapidly worsened. The case was discussed with two different
surgical teams,who deemed the patient at high risk for redoing
AVRbecause of advanced age, the risks of the redoprocedure,
and comorbidities: the logistic EuroScore was 31.8%. Thus,
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the patient was transferred to our department to evaluate the
feasibility of PAVR. Cardiac catheterization and angiography
confirmed the severity of aortic regurgitation with left ven-
tricular dysfunction, increased ventricular filling pressure,
pulmonary hypertension, and decreased cardiac index. The
computed tomographic scan of the aorta and iliac and femoral
arteries showed a moderate degree of wall calcification in the
ascending aorta, with aortic root and annular dimensions ame-
nable forPAVR; the femoral and iliac arteries showeda caliber
suitable for large sheath insertion. The procedure was per-
formedwith the patient undermild sedation and local anesthe-
sia by a percutaneous retrograde approach.Over an18F sheath
percutaneously inserted in the right femoral artery, the valve
(29 mm, third-generation CoreValve Revalving system) was
introduced and retrogradely advanced under fluoroscopic
guidance over a stiff wire in the ascending aorta across the
pre-existing prosthesis plane. After careful evaluation of pros-
thesis position by angiography, the prosthesis was progres-
sively deployed and the delivery system retrieved. Aortic
angiogram after deployment showed the correct positioning
of the prosthesis with a trivial paravalvular leak (Figure 1);
no transvalvular gradientwas detected. Finally, the 18F sheath
was removed and hemostasis of the right femoral artery was
successfully obtained by knotting the sutures of a preposi-
tioned suture-based closure device (Prostar XL 10F; Abbott
Vascular, Alameda, Calif). The in-hospital course was un-
eventful and the patient was discharged at home on day 6 after
the procedure.Dual antiplatelet treatment was prescribed for 6
months. At 6 months’ follow-up, the patient remained free of
adverse events, with persistent New York Heart Association
functional class I; a transthoracic echocardiogram confirmed
good performance of the implanted prosthesis with neither
aortic regurgitation nor significant transprosthetic gradient.
DISCUSSION
Recently, Wenaweser and associates2 reported the first
case of CoreValve implantation for the treatment of aortic
regurgitation in a degenerating bioprosthesis. They used
rdiovascular Surgery c Volume 138, Number 4 1027
